Transgene is designing and developing next-generation immunotherapeutics against cancer

One patient, one cancer, one vaccine

TG4050 is an individualized neoantigen cancer vaccines from Transgene’s myvac® platform, based on multiple advanced genetic engineering technologies and cutting-edge artificial intelligence capabilities. TG4050 is being evaluated in a Phase I/II clinical trial.

  TG4050 video
 Watch Alessandro Riva presenting first clinical benefits of neoantigen cancer vaccine, TG4050, in head & neck cancer at AACR 2024

Innovative technologies

Push the boundaries of immunotherapy

Transgene combines cutting-edge technologies, a multidisciplinary team and a prestigious international network.

Discover our myvac® platform
Discover our invir.IO® platform

Oncolytic viruses

A new generation of products

These innovative multifunctional OVs, from Transgene’s invir.IO® platform, are able to modulate the tumor microenvironment to better attack cancer.

  Oncolytic viruses video

Three therapeutic approaches

Transgene’s immunotherapies harness the mechanisms of the immune response to enable the patient’s body to fight against disease. 

 

A pioneer in viral vectors engineering, we have one ambition: design innovative treatments in the fight against cancer.

Transgene sa
400 Boulevard Gonthier d’Andernach - Parc d'Innovation - CS80166
67405 Illkirch Graffenstaden Cedex - France |
Tel. : + 33 (0) 3 88 27 91 00

 

© 2025 Transgene - All rights reserved
Credits